Outcomes of Levofloxacin-Based Regimens in Adults With Severe Community-Acquired Pneumonia Requiring ICU Admission: A Single-Center Retrospective Cohort From Jazan, Saudi Arabia
Abstract
Background
Levofloxacin is widely used in combination regimens for severe community-acquired pneumonia (CAP) in the ICU; however, real-world outcome data from resource-limited settings remain scarce.
Objective:
To evaluate 28-day mortality and key clinical/safety outcomes among adults with severe CAP requiring ICU admission who received levofloxacin-based regimens at Abu-Arish General Hospital.
Methods
We conducted a retrospective cohort study that examined patient data captured through an electronic medical system at the Abu Arish General Hospital between 2021 and 2022 (Single‑center retrospective cohort (dates), Abu‑Arish General Hospital ICU). We used the repeated measures ANCOVA to investigate the effect of Levofloxacin on a wide range of medical parameters. Data analysis was performed with SPSS statistics (Version 25).
Results
A total of 93 patients were included in this study. The study examined the impact of levofloxacin on various medical parameters, including age, weight, height, BMI, initial dosage, comorbid diseases and sex. The adjusted mean differences between before and after Levofloxacin administration revealed significant changes in a variety of medical parameters, including hepatic markers and hematologic indices.
Conclusion
Levofloxacin therapy can produce change in baseline clinical characteristics of critical ill patients in the intensive care unit. We need to investigate the tolerability of this therapy in terms the severity of side effects on a large…
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 93 participants or records.
Read the paper
Related studies
- Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matching
- Thiophenes—Naturally Occurring Plant Metabolites: Biological Activities and In Silico Evaluation of Their Potential as Cathepsin D Inhibitors
- Inhalable Mannosylated Rifampicin–Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy
- Association between cord blood 25-hydroxyvitamin D concentrations and respiratory tract infections in the first 6 months of age in a Korean population: a birth cohort study (COCOA)
- GC-MS Analysis and Biomedical Therapy of Oil from n-Hexane Fraction of Scutellaria edelbergii Rech. f.: In Vitro, In Vivo, and In Silico Approach
- Novel Pharmacokinetic/Pharmacodynamic Parameters Quantify the Exposure–Effect Relationship of Levofloxacin against Fluoroquinolone-Resistant Escherichia coli
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.